TY - JOUR T1 - Estimating the causal effect of genetic liability to prevalent disease on hospital costs using Mendelian Randomization JF - medRxiv DO - 10.1101/2020.07.09.20149906 SP - 2020.07.09.20149906 AU - Padraig Dixon AU - Sean Harrison AU - William Hollingworth AU - Neil M Davies AU - George Davey Smith Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/07/11/2020.07.09.20149906.abstract N2 - BACKGROUND Accurate measurement of the effects of disease status on healthcare cost is important in the pragmatic evaluation of interventions but is complicated by endogeneity biases due to omitted variables and reverse causality. Mendelian Randomization, the use of random perturbations in germline genetic variation as instrumental variables, can avoid these limitations. We report a novel Mendelian Randomization analysis of the causal effect of liability to disease on healthcare costs.METHODS We used Mendelian Randomization to model the causal impact on inpatient hospital costs of liability to six highly prevalent diseases: asthma, eczema, migraine, coronary heart disease, type 2 diabetes, and major depressive disorder. We identified genetic variants from replicated genome-wide associations studies and estimated their association with inpatient hospital costs using data from UK Biobank, a large prospective cohort study of individuals linked to records of hospital care. We assessed potential violations of the instrumental variable assumptions, particularly the exclusion restriction (i.e. variants affecting costs through alternative paths). We also conducted new genome wide association studies of hospital costs within the UK Biobank cohort as a further “split sample”sensitivity analysis.RESULTS We analyzed data on 307,032 individuals. Genetic variants explained only a small portion of the variance in each disease phenotype. Liability to coronary heart disease had substantial impacts (mean per person per year increase in costs from allele score Mendelian Randomization models: £712 (95% confidence interval: £238 to £1,186)) on inpatient hospital costs in causal analysis, but other results were imprecise. There was concordance of findings across varieties of sensitivity analyses, including stratification by sex, and those obtained from the split sample analysis.CONCLUSION A novel Mendelian Randomization analysis of the causal effect of liability to disease on healthcare cost demonstrates that this type of analysis is feasible and informative in this context. There was concordance across data sources and across methods bearing different assumptions. Selection into the relatively healthy UK Biobank cohort and the modest proportion of variance in disease status accounted for by the allele scores reduced the precision of our estimates. We therefore could not exclude the possibility of substantial costs due to these diseases.JEL Classification Numbers H51, I10, I11, I18,Competing Interest StatementThe authors have declared no competing interest.Funding StatementPD, GDS, SH and NMD are members of the MRC Integrative Epidemiology Unit at the University of Bristol which is supported by the Medical Research Council and the University of Bristol (MC_UU_00011/1). PD acknowledges support from a Medical Research Council Skills Development Fellowship (MR/P014259/1). NMD is supported by a Norwegian Research Council Grant number 295989. SH was supported by Health Foundation grant Social and economic consequences of health: Causal inference methods and longitudinal, intergenerational data, part of the Health Foundation Social and Economic Value of Health Programme (Grant ID: 807293).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval for UK Biobank was received from the North West Haydock Research Ethics Committee (reference 11/NW/0382).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe principal source of data used in this study is the UK Biobank, the terms of access of which do not permit data sharing by third parties. However, data used in this study are available via application to UK Biobank. Other data used int he study are drawn from publicly available genome-wide association summary statistics, the sources for which are cited in the main text. ER -